GM-CSF Blockade Discovery Service for CRS Management

At Creative Biolabs, our team is dedicated to working with you to design specific solutions and getting accurate results to ensure critical decisions for your drug discovery and development programs. Empowered by extensive experiences in T cell-engaging therapies, now we offer drug discovery and development services for GM-CSF blockade therapies that can control the cytokine release syndrome (CRS) toxicities caused by T cell-engaging immunotherapies.

Background

CAR-T cell therapy has emerged as a novel and potentially revolutionary therapy to treat cancer. While its application is limited by the emergence of potentially fatal toxicities induced by the development of CRS and neurotoxicity. The development and toxicities of CRS are associated with in vivo T cell activation, expansion and massive production of cytokines including IL-6, Interferon-γ, MCP-1, and GM-CSF. Studies have demonstrated that monocytes and macrophages contribute to the toxicities of CAR-T cell therapy. This knowledge suggests that GM-CSF can be a therapeutic target in the development of both CRS and neurotoxicity, and GM-CSF blockade might be a potential strategy to manage the CRS toxicities.

GM-CSF Blockade for CRS Management

Studies have demonstrated that the anti-GM-CSF antibody can inhibit neuroinflammation and CRS in CART19 cell therapy without affecting CAR-T cell function. Blocking GM-CSF is treated as a novel approach to abrogate neuroinflammation and CRS, while enhancing CAR-T cell function. As an experienced CRO providing antibody discovery, antibody engineering, and antibody manufacturing services, now we launch anti-GM-CSF antibody discovery and development solutions with CRS management potential for our clients. We have extensive capability to provide comprehensive solutions due to our huge repository of various platforms, innovative technologies, and rich experiences of our scientists. We are dedicated to benefiting you, your program, and the patients in need of CRS management who receive the T cell-engaging therapies.

Fig.1 The roles of GM-CSF.¹

Highlights of GM-CSF Blockade

• Blocking GM-CSF can prevent CRS and neuro-inflammation during CAR-T therapy as a viable therapeutic solution
• Blocking GM-CSF can enhance the anti-tumor functions of CAR-T cell therapy

Our Advantages

• High-throughput screening
• Integrated, multidisciplinary drug discovery expertise
• Get better data faster

Creative Biolabs offers unique and proprietary solutions that span the entire drug discovery and development processes. Outsourcing your drug discovery program to us will help you shorten the development timeline and fasten the success of your program. If you have any drug discovery and development requirements, please don't hesitate to contact us.

Reference

1. Shiomi, Aoi, and Takashi Usui. "Pivotal roles of GM‐CSF in autoimmunity and inflammation." Mediators of inflammation 2015.1 (2015): 568543. Distributed under Open Access license CC BY 4.0, without modification.